Published in J Immunol on March 01, 1979
Relative efficacy of human monocytes and dendritic cells as accessory cells for T cell replication. J Exp Med (1983) 3.20
Subpopulations of circulating B cells and regulatory T cells involved in in vitro immunoglobulin E production in atopic patients with elevted serum immunoglobulin E. J Clin Invest (1980) 1.68
Regulation of cellular function by products of lysosomal enzyme activity: elimination of human natural killer cells by a dipeptide methyl ester generated from L-leucine methyl ester by monocytes or polymorphonuclear leukocytes. Proc Natl Acad Sci U S A (1985) 1.63
Activation of human B cells by phosphorothioate oligodeoxynucleotides. J Clin Invest (1996) 1.57
Immune responses to the lipopolysaccharides and capsular polysaccharides of Haemophilus pleuropneumoniae in convalescent and immunized pigs. Infect Immun (1986) 1.50
Antigen-specific human T-cell clones: development of clones requiring HLA-DR-compatible presenting cells for stimulation in presence of antigen. Proc Natl Acad Sci U S A (1981) 1.44
Human endothelial cell-lymphocyte interaction. Endothelial cells function as accessory cells necessary for mitogen-induced human T lymphocyte activation in vitro. J Clin Invest (1981) 1.31
Monoclonal antibodies against HLA-DR antigens replace T helper cells in activation of B lymphocytes. Proc Natl Acad Sci U S A (1983) 1.28
The immunological consequences of gold therapy: a prospective study in patients with rheumatoid arthritis. Clin Exp Immunol (1986) 1.27
Inhibition of human helper T cell function in vitro by D-penicillamine and CuSO4. J Clin Invest (1980) 1.13
Immunosuppression by D-penicillamine in vitro. Inhibition of human T lymphocyte proliferation by copper- or ceruloplasmin-dependent generation of hydrogen peroxide and protection by monocytes. J Clin Invest (1984) 1.06
Delineation of the functional capacity of human neonatal lymphocytes. J Clin Invest (1991) 1.00
Interaction of pokeweed mitogen with monocytes in the activation of human lymphocytes. Immunology (1983) 0.98
Role of monocytes in polyclonal immunoglobulin production stimulated by sonicates of periodontally associated bacteria. Infect Immun (1983) 0.97
In vitro studies of poison oak immunity. I. In vitro reaction of human lymphocytes to urushiol. J Clin Invest (1979) 0.95
Suppression of in vitro lymphocyte DNA synthesis by killed Pseudomonas aeruginosa. Infect Immun (1983) 0.95
Prolylcarboxypeptidase (angiotensinase C) in human lung and cultured cells. J Clin Invest (1981) 0.95
Pokeweed-mitogen induced lymphocyte proliferation: the effect of stimulation on mononuclear phagocytic cells. Immunology (1980) 0.94
Proliferative signals for suppressor T cells. Helper cells stimulated with pokeweed mitogen in vitro produce a suppressor cell growth factor. J Clin Invest (1986) 0.91
Studies on immunoregulatory mechanisms in acute and chronic hepatitis B. Clin Exp Immunol (1983) 0.91
Hyper-immunoglobulin G2 production by B cells from patients with localized juvenile periodontitis and its regulation by monocytes. Infect Immun (1996) 0.90
Studies on the mechanism of peptidoglycan- and lipopolysaccharide-induced polyclonal activation. Infect Immun (1982) 0.89
Immunomodulatory effect of procainamide in man. Inhibition of human suppressor T-cell activity in vitro. J Clin Invest (1983) 0.87
Regulation of human B cell activation by prostaglandin E2. Suppression of the generation of immunoglobulin-secreting cells. J Clin Invest (1985) 0.86
Human tonsil B lymphocyte function. I. The proliferative response to Staphylococcus aureus and pokeweed mitogen in relation to surface heavy chains mu and delta. Clin Exp Immunol (1984) 0.86
Macrophage-lymphocyte interaction in response to a bacterial antigen (E. coli). Clin Exp Immunol (1982) 0.86
T-cell regulation of pokeweed-mitogen-induced polyclonal immunoglobulin production in mice. II. Mechanism of the induction of suppressor T cells. Immunology (1982) 0.84
Monocyte suppression of Fusobacterium nucleatum-induced human polyclonal B-lymphocyte activation. Infect Immun (1984) 0.83
In vitro effect of (3-amino-1-hydroxypropylidene)-1,1-bisphosphonic acid (APD) on the function of mononuclear phagocytes in lymphocyte proliferation. Immunology (1982) 0.83
T suppressor cell growth factor and anti-CD3 antibodies stimulate reciprocal subsets of T lymphocytes. J Exp Med (1987) 0.81
Spontaneous and induced immunoglobulin secretion by synovial fluid B lymphocytes in rheumatoid arthritis. Ann Rheum Dis (1984) 0.81
Prostaglandin-mediated immunoregulation: reduced sensitivity of in vitro immunoglobulin production to indomethacin in rheumatoid arthritis. Clin Exp Immunol (1983) 0.80
Analysis of the transcriptional program of developing induced regulatory T cells. PLoS One (2011) 0.79
Human peripheral blood B cell subpopulations: surface IgD+ cells respond to pokeweed mitogen with plasma cell differentiation. Clin Exp Immunol (1986) 0.78
Human B cell function in responder and non-responder individuals. II. The role of T helper cells in promoting the PWM-induced B cell production of immunoprotein. Clin Exp Immunol (1983) 0.78
Suppression of Staphylococcus aureus Cowan I-induced immunoglobulin synthesis in vitro: discrimination between the presence of suppressor T cell precursors and effectors. Clin Exp Immunol (1986) 0.77
The effect of prednisolone in vitro on immunoglobulin production in primary biliary cirrhosis. Clin Exp Immunol (1986) 0.77
Analysis of impaired in vitro immunoglobulin synthesis in rheumatoid arthritis. Ann Rheum Dis (1990) 0.76
Effects of a human urinary mitogen on subpopulations of peripheral blood mononuclear leukocytes. Clin Exp Immunol (1986) 0.75
Defective immunoglobulin secretion in response to pokeweed mitogen in sarcoidosis. Clin Exp Immunol (1982) 0.75
Mouse rosette positive B cells fail to synthesize immunoglobulin following incubation with pokeweed mitogen. Clin Exp Immunol (1983) 0.75
Measurement of single-cell DNA synthesis by pokeweed mitogen-stimulated mononuclear cells with combined light and scanning electron microscopy. Immunology (1986) 0.75
High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol (1999) 10.86
Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A (1994) 8.92
Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med (1982) 8.74
Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med (1985) 8.21
A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science (1986) 8.07
A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med (1987) 7.33
Cyclooxygenase in biology and disease. FASEB J (1998) 7.17
Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci U S A (1994) 6.93
Adoptive transfer of cloned melanoma-reactive T lymphocytes for the treatment of patients with metastatic melanoma. J Immunother (2001) 5.83
Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity. J Clin Oncol (1998) 5.74
Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med (1994) 5.67
Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol (1989) 5.44
gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J Exp Med (1998) 5.24
Biological activity of recombinant human interleukin-2 produced in Escherichia coli. Science (1984) 4.90
Non-Hodgkin's lymphomas. IV. Clinicopathologic correlation in 405 cases. Cancer (1973) 4.66
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol (1995) 4.42
Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol (1995) 4.31
Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA (1999) 4.25
High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am (2000) 4.19
Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes. J Exp Med (1994) 3.94
T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years. Science (1995) 3.87
Vaccination with a recombinant vaccinia virus encoding a "self" antigen induces autoimmune vitiligo and tumor cell destruction in mice: requirement for CD4(+) T lymphocytes. Proc Natl Acad Sci U S A (1999) 3.66
Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol (1989) 3.60
Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol (1996) 3.45
Analysis of the heavy chain repertoire of human peripheral B cells using single-cell polymerase chain reaction. J Immunol (1995) 3.31
Identification of human cancers deficient in antigen processing. J Exp Med (1993) 3.21
Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. J Immunol Methods (1987) 3.09
Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science (1984) 3.08
Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. J Exp Med (1997) 3.07
Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol (2001) 3.07
Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2. J Exp Med (1985) 3.05
Disturbed peripheral B lymphocyte homeostasis in systemic lupus erythematosus. J Immunol (2000) 3.05
Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma. J Clin Oncol (2001) 3.05
Phenotype of the accessory cell necessary for mitogen-stimulated T and B cell responses in human peripheral blood: delineation by its sensitivity to the lysosomotropic agent, L-leucine methyl ester. J Immunol (1983) 3.04
Apoptotic death of CD8+ T lymphocytes after immunization: induction of a suppressive population of Mac-1+/Gr-1+ cells. J Immunol (1998) 3.03
Identification of specific cytolytic immune responses against autologous tumor in humans bearing malignant melanoma. J Immunol (1987) 3.03
Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum (2004) 3.00
A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med (1996) 2.99
The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med (1984) 2.95
High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol (1999) 2.94
The value of laparotomy and splenectomy in the staging of Hodgkin's disease. Cancer (1969) 2.93
Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2. J Immunol (1986) 2.82
Recognition of tyrosinase by tumor-infiltrating lymphocytes from a patient responding to immunotherapy. Cancer Res (1994) 2.74
In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. J Immunol (1985) 2.73
Enhancement of cellular immunity in melanoma patients immunized with a peptide from MART-1/Melan A. Cancer J Sci Am (1997) 2.71
Differential utilization of ICAM-1 and VCAM-1 during the adhesion and transendothelial migration of human T lymphocytes. J Immunol (1991) 2.69
Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. J Exp Med (1983) 2.67
Identification of a gene encoding a melanoma tumor antigen recognized by HLA-A31-restricted tumor-infiltrating lymphocytes. J Exp Med (1995) 2.54
Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res (1981) 2.49
Active immunotherapy of cancer with a nonreplicating recombinant fowlpox virus encoding a model tumor-associated antigen. J Immunol (1995) 2.45
Analysis of the human VH gene repertoire. Differential effects of selection and somatic hypermutation on human peripheral CD5(+)/IgM+ and CD5(-)/IgM+ B cells. J Clin Invest (1997) 2.44
Macrophage-lymphocyte interaction. II. Antigen-mediated physical interactions between immune guinea pig lymph node lymphocytes and syngeneic macrophages. J Exp Med (1975) 2.44
Regression of a disseminated syngeneic solid tumor by systemic transfer of lymphoid cells expanded in interleukin 2. J Exp Med (1982) 2.42
Isolation and characterization of human peripheral blood dendritic cells. J Immunol (1993) 2.33
Passive immunotherapy of cancer in animals and man. Adv Cancer Res (1977) 2.32
Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes. J Exp Med (1996) 2.31
The role of cell surface recognition structures in the initiation of MHC-unrestricted 'promiscuous' killing by T cells. Immunol Today (1989) 2.31
Comparison of computed and conventional whole lung tomography in detecting pulmonary nodules: a prospective radiologic-pathologic study. AJR Am J Roentgenol (1978) 2.29
Antigen presentation by interferon-gamma-treated endothelial cells and fibroblasts: differential ability to function as antigen-presenting cells despite comparable Ia expression. J Immunol (1985) 2.27
The prevalence and clinical impact of fibromyalgia in systemic lupus erythematosus. Arthritis Rheum (1994) 2.26
Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med (1988) 2.26
Shared human melanoma antigens. Recognition by tumor-infiltrating lymphocytes in HLA-A2.1-transfected melanomas. J Immunol (1992) 2.19
Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J Immunol (1999) 2.17
Stromal cell-derived factor-1-CXC chemokine receptor 4 interactions play a central role in CD4+ T cell accumulation in rheumatoid arthritis synovium. J Immunol (2000) 2.17
Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J Exp Med (1996) 2.17
Surgical staging of abdominal involvement in unselected patients with Hodgkin's disease. Radiology (1970) 2.16
Cytokine enhancement of DNA immunization leads to effective treatment of established pulmonary metastases. J Immunol (1996) 2.15
Immunization of patients with melanoma peptide vaccines: immunologic assessment using the ELISPOT assay. Cancer J Sci Am (1998) 2.14
Interferon gamma and tumor necrosis factor have a role in tumor regressions mediated by murine CD8+ tumor-infiltrating lymphocytes. J Exp Med (1991) 2.14
The fate of interleukin-2 after in vivo administration. J Immunol (1983) 2.13
Antigen processing in vivo and the elicitation of primary CTL responses. J Immunol (1995) 2.12
Antigen expression by dendritic cells correlates with the therapeutic effectiveness of a model recombinant poxvirus tumor vaccine. Proc Natl Acad Sci U S A (1997) 2.11
Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst (1996) 2.11
Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. Annu Rev Immunol (1986) 2.08
T-cell clones from melanoma patients immunized against an anchor-modified gp100 peptide display discordant effector phenotypes. Cancer J (2001) 2.08
Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am (2000) 2.06
Accessory cell independent proliferation of human T4 cells stimulated by immobilized monoclonal antibodies to CD3. J Immunol (1987) 2.03
IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J Immunol (1995) 2.02
Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science (1999) 2.01
Macrophage-lymphocyte interaction. I. Characteristics of the antigen-independent-binding of guinea pig thymocytes and lymphocytes to syngeneic macrophages. J Exp Med (1973) 2.00
Evidence for an orderly progression in the spread of Hodgkin's disease. Cancer Res (1966) 2.00
Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J Clin Oncol (1989) 2.00
Immunization against epitopes in the human melanoma antigen gp100 following patient immunization with synthetic peptides. Cancer Res (1996) 1.99
Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cells. J Exp Med (1983) 1.99
Interleukin 4 promotes the growth of tumor-infiltrating lymphocytes cytotoxic for human autologous melanoma. J Exp Med (1988) 1.98
Immunotherapy of cancer using interleukin 2: current status and future prospects. Immunol Today (1988) 1.97
The protein of human erythrocyte membranes. I. Preparation, solubilization, and partial characterization. J Biol Chem (1968) 1.97
Tumor necrosis factor-alpha enhances cytolytic activity of human natural killer cells. J Immunol (1987) 1.97
CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production. Proc Natl Acad Sci U S A (2001) 1.96
Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2. J Immunol (1987) 1.96
Development of optimal bicistronic lentiviral vectors facilitates high-level TCR gene expression and robust tumor cell recognition. Gene Ther (2008) 1.94
The grading of soft tissue sarcomas. Results of a clinicohistopathologic correlation in a series of 163 cases. Cancer (1984) 1.93
Circulating and mitogen-induced immunoglobulin-secreting cells in human peripheral blood: evaluation by a modified reverse hemolytic plaque assay. J Immunol (1978) 1.93
Hematologic neoplasia in patients treated for Hodgkin's disease. N Engl J Med (1977) 1.93
Human CD4+ T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc Natl Acad Sci U S A (1994) 1.91
Phenotypic analysis of synovial tissue and peripheral blood lymphocytes isolated from patients with rheumatoid arthritis. Arthritis Rheum (1988) 1.90